Dr. Ionescu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Janssen Pharmaceuticals
3210 Merryfield Row
San Diego, CA 92121- Is this information wrong?
Education & Training
- National Institutes of Health Clinical CenterResidency, Psychiatry, 2012 - 2014
- George Washington UniversityResidency, Psychiatry, 2009 - 2012
- Pennsylvania State University College of MedicineClass of 2009
Certifications & Licensure
- CA State Medical License 2017 - 2024
- MA State Medical License 2014 - 2018
- DC State Medical License 2009 - 2014
- VA State Medical License 2009 - 2012
- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 3 citationsEffect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.Anna Feeney, Bettina B Hoeppner, Marlene P Freeman, Martina Flynn, Dan V Iosifescu, Madhukar H Trivedi, Gerard Sanacora, Sanjay J Mathew, Charles DeBattista, Dawn F Io...> ;The Journal of Clinical Psychiatry. 2022 Nov 14
- 30 citationsEsketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.Carla M. Canuso, Dawn F. Ionescu, Xiang Li, Xin Qiu, Rosanne Lane, Ibrahim Turkoz, Abigail I. Nash, Tricia J Lopena, Dong-Jing Fu> ;Journal of Clinical Psychopharmacology. 2021 Sep 1
- 8 citationsThe effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.Ella Daly, Ibrahim Turkoz, Giacomo Salvadore, Maggie Fedgchin, Dawn F. Ionescu, H. Lynn Starr, Stephane Borentain, Madhukar H. Trivedi, Michael E. Thase, Jaskaran Singh> ;Depression and Anxiety. 2021 Jul 22
- Join now to see all
Journal Articles
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Press Mentions
- Ketamine May Reduce Active Suicidal Thoughts in Patients with Treatment-Resistant DepressionMay 13th, 2016
- Intravenous Ketamine May Rapidly Reduce Suicidal Thinking in Depressed PatientsMay 10th, 2016
- Drug Holds Promise to Fight Acute DepressionFebruary 16th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: